07:49 AM EDT, 09/16/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Saturday that a phase 1b/2 study of Rybrevant combined with chemotherapy showed "promising rapid and durable antitumor activity" in patients with metastatic colorectal cancer who have not previously received anti-epidermal growth factor receptor therapy.

The company said 43 patients who received Rybrevant with either FOLFOX or FOLFIRI achieved an overall response rate of 49%, with a median duration of response of 7.4 months and a median progression-free survival of 7.5 months.

Disease control was achieved in 88% of patients, and 53% of those with liver metastases experienced significant tumor reduction while 21% proceeded to surgery, Johnson & Johnson ( JNJ ) said.

The safety profile of Rybrevant combined with chemotherapy was manageable, with no new safety signals observed, the company added.

Price: 165.81, Change: +0.29, Percent Change: +0.18